XEN1101 (Azetukalner)

How it works

An oral small molecule (Xenon Pharmaceuticals) that opens Kv7 potassium channels to dampen excessive neuronal excitability, the same channel family the Potassium Channel Dysfunction hypothesis implicates in tinnitus. Xenon filed its FDA NDA for focal epilepsy in Sep 2026 based on positive Phase 2b/3 data, but separately paused its MDD/bipolar depression trials the same month after neuropsychiatric adverse events (confusion, aphasia, ataxia) emerged in the larger Phase 3 depression population. No dedicated tinnitus trial has been run for either indication. Included as a mechanistically plausible but untested candidate, a clinical-stage Kv7 opener that could, in principle, be repurposed for the dorsal-cochlear-nucleus hyperexcitability the hypothesis describes.

This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.